About this Journal Submit a Manuscript Table of Contents
International Journal of Proteomics
Volume 2011 (2011), Article ID 365350, 5 pages
http://dx.doi.org/10.1155/2011/365350
Review Article

Proteomics in Pancreatic Cancer Research

Department of Gastroenterology, Changhai Hospital, The Second Military Medical University, Shanghai 200433, China

Received 1 March 2011; Revised 13 April 2011; Accepted 29 June 2011

Academic Editor: Mandi Murph

Copyright © 2011 Ruihui Geng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Hidalgo, “Pancreatic cancer,” The New England Journal of Medicine, vol. 362, no. 17, pp. 1605–1617, 2010.
  2. V. C. Wasinger, S. J. Cordwell, A. Cerpa-Poljak et al., “Progress with gene-product mapping of the mollicutes: mycoplasma genitalium,” Electrophoresis, vol. 16, no. 7, pp. 1090–1094, 1995. View at Scopus
  3. R. L. Moritz, A. R. Skandarajah, H. Ji, et al., “Proteomic analysis of colorectal cancer: prefractionation strategies using two-dimensional free-flow electrophoresis,” Comparative and Functional Genomics, vol. 6, no. 4, pp. 236–243, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. T. Rabilloud, “Two-dimensional gel electrophoresis in proteomics: old, old fashioned, but it still climbs up the mountains,” Proteomics, vol. 2, no. 1, pp. 3–10, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. Y. Rong, D. Jin, C. Hou et al., “Proteomics analysis of serum protein profiling in pancreatic cancer patients by DIGE: up-regulation of mannose-binding lectin 2 and myosin light chain kinase 2,” BMC Gastroenterology, vol. 10, article 68, 2010. View at Publisher · View at Google Scholar · View at PubMed
  6. J. Minden, “Comparative proteomics and difference gel electrophoresis,” BioTechniques, vol. 43, no. 6, pp. 739–745, 2007. View at Publisher · View at Google Scholar
  7. G. M. Liumbruno, “Proteomics: applications in transfusion medicine,” Blood Transfusion, vol. 6, no. 2, pp. 70–85, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. M. J. Page, T. A. Griffiths, M. R. Bleackley, et al., “Proteomics: applications relevant to transfusion medicine,” Transfusion Medicine Reviews, vol. 20, no. 1, pp. 63–74, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. B. F. Cravatt, G. M. Simon, and J. R. Yates III, “The biological impact of mass-spectrometry-based proteomics,” Nature, vol. 450, no. 7172, pp. 991–1000, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. D. H. Conrad, J. Goyette, and P. S. Thomas, “Proteomics as a method for early detection of cancer: a review of proteomics, exhaled breath condensate, and lung cancer screening,” Journal of General Internal Medicine, vol. 23, supplement 1, pp. 78–84, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. A. Motoyama and J. R. Yates III, “Multidimensional LC separations in shotgun proteomics,” Analytical Chemistry, vol. 80, no. 19, pp. 7187–7193, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. B. Domon and R. Aebersold, “Mass spectrometry and protein analysis,” Science, vol. 312, no. 5771, pp. 212–217, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. M. R. Roe and T. J. Griffin, “Gel-free mass spectrometry-based high throughput proteomics: tools for studying biological response of proteins and proteomes,” Proteomics, vol. 6, no. 17, pp. 4678–4687, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. S. Tonack, M. Aspinall-O'Dea, R. E. Jenkins et al., “A technically detailed and pragmatic protocol for quantitative serum proteomics using iTRAQ,” Journal of Proteomics, vol. 73, no. 2, pp. 352–356, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. Y. Zhao, W. N. Lee, S. Lim et al., “Quantitative proteomics: measuring protein synthesis using 15N amino acid labeling in pancreatic cancer cells,” Analytical Chemistry, vol. 81, no. 2, pp. 764–771, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. D. A. Hall, J. Ptacek, and M. Snyder, “Protein microarray technology,” Mechanisms of Ageing and Development, vol. 128, no. 1, pp. 161–167, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. Q. Xu and K. S. Lam, “Protein and chemical microarrays-powerful tools for proteomics,” Journal of Biomedicine and Biotechnology, vol. 2003, no. 5, pp. 257–266, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. C. Schröder, A. Jacob, S. Tonack et al., “Dual-color proteomic profiling of complex samples with a microarray of 810 cancer-related antibodies,” Molecular and Cellular Proteomics, vol. 9, no. 6, pp. 1271–1280, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. Y. P. Lim, “Mining the tumor phosphoproteome for cancer markers,” Clinical Cancer Research, vol. 11, no. 9, pp. 3163–3169, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. T. Nagashima, M. Oyama, H. Kozuka-Hata, et al., “Phosphoproteome and transcriptome analyses of ErbB ligand-stimulated MCF-7 cells,” Cancer Genomics and Proteomics, vol. 5, no. 3-4, pp. 161–168, 2008. View at Scopus
  21. S. A. Johnson and T. Hunter, “Phosphoproteomics finds its timing,” Nature Biotechnology, vol. 22, no. 9, pp. 1093–1094, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. H. Ijichi, M. Otsuka, K. Tateishi et al., “Smad4-independent regulation of p21/WAF1 by transforming growth factor-β,” Oncogene, vol. 23, no. 5, pp. 1043–1051, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. A. Jazag, H. Ijichi, F. Kanai et al., “Smad4 silencing in pancreatic cancer cell lines using stable RNA interference and gene expression profiles induced by transforming growth factor-β,” Oncogene, vol. 24, no. 4, pp. 662–671, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. K. Mikuriya, Y. Kuramitsu, S. Ryozawa et al., “Expression of glycolytic enzymes is increased in pancreatic cancerous tissues as evidenced by proteomic profiling by two-dimensional electrophoresis and liquid chromatography-mass spectrometry/mass spectrometry,” International Journal of Oncology, vol. 30, no. 4, pp. 849–855, 2007. View at Scopus
  25. L. Dai, C. Li, K. A. Shedden et al., “Quantitative proteomic profiling studies of pancreatic cancer stem cells,” Journal of Proteome Research, vol. 9, no. 7, pp. 3394–3402, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. L. D. Roy, M. Sahraei, D. B. Subramani et al., “MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition,” Oncogene, vol. 30, no. 12, pp. 1449–1459, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. D. Basso, E. Greco, P. Fogar et al., “Pancreatic cancer-associated diabetes mellitus: an open field for proteomic applications,” Clinica Chimica Acta, vol. 357, no. 2, pp. 184–189, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. F. Navaglia, P. Fogar, D. Basso et al., “Pancreatic cancer biomarkers discovery by surface-enhanced laser desorption and ionization time-of-flight mass spectrometry,” Clinical Chemistry and Laboratory Medicine, vol. 47, no. 6, pp. 713–723, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. J. Koopmann, P. Buckhaults, D. A. Brown et al., “Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers,” Clinical Cancer Research, vol. 10, no. 7, pp. 2386–2392, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Matsubara, K. Honda, M. Ono et al., “Reduced plasma level of CXC chemokine ligand 7 in patients with pancreatic cancer,” Cancer Epidemiology Biomarkers and Prevention, vol. 20, no. 1, pp. 160–171, 2011. View at Publisher · View at Google Scholar · View at PubMed
  31. T. H. Patwa, C. Li, L. M. Poisson et al., “The identification of phosphoglycerate kinase-1 and histone H4 autoantibodies in pancreatic cancer patient serum using a natural protein microarray,” Electrophoresis, vol. 30, no. 12, pp. 2215–2226, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. Z. L. Sun, Y. Zhu, F. Q. Wang et al., “Serum proteomic-based analysis of pancreatic carcinoma for the identification of potential cancer biomarkers,” Biochimica et Biophysica Acta, vol. 1774, no. 6, pp. 764–771, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. G. M. Fiedler, A. B. Leichtle, J. Kase et al., “Serum peptidome profiling revealed platelet factor 4 as a potential discriminating peptide associated with pancreatic cancer,” Clinical Cancer Research, vol. 15, no. 11, pp. 3812–3819, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. G. A. Scheele, “Two dimensional gel analysis of soluble proteins. Characterization of guinea pig exocrine pancreatic proteins,” Journal of Biological Chemistry, vol. 250, no. 14, pp. 5375–5385, 1975. View at Scopus
  35. M. Tian, Y. Z. Cui, G. H. Song et al., “Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients,” BMC Cancer, vol. 8, article 241, 2008. View at Publisher · View at Google Scholar · View at PubMed
  36. K. Kojima, S. Asmellash, C. A. Klug, et al., “Applying proteomic-based biomarker tools for the accurate diagnosis of pancreatic cancer,” Journal of Gastrointestinal Surgery, vol. 12, no. 10, pp. 1683–1690, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. D. Cecconi, M. Donadelli, A. Scarpa et al., “Proteomic analysis of pancreatic ductal carcinoma cells after combined treatment with gemcitabine and trichostatin A,” Journal of Proteome Research, vol. 4, no. 6, pp. 1909–1916, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. S. Mori-Iwamoto, Y. Kuramitsu, S. Ryozawa et al., “Proteomics finding heat shock protein 27 as a biomarker for resistance of pancreatic cancer cells to gemcitabine,” International Journal of Oncology, vol. 31, no. 6, pp. 1345–1350, 2007. View at Scopus
  39. K. Taba, Y. Kuramitsu, S. Ryozawa et al., “KNK437 downregulates heat shock protein 27 of pancreatic cancer cells and enhances the cytotoxic effect of gemcitabine,” Chemotherapy, vol. 57, no. 1, pp. 12–16, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. Y. Kuramitsu, K. Taba, S. Ryozawa et al., “Identification of up- and down-regulated proteins in gemcitabine-resistant pancreatic cancer cells using two-dimensional gel electrophoresis and mass spectrometry,” Anticancer Research, vol. 30, no. 9, pp. 3367–3372, 2010. View at Scopus
  41. K. Taniuchi, H. Nakagawa, T. Nakamura et al., “Down-regulation of RAB6KIFL/KIF20A, a kinesin involved with membrane trafficking of discs large homologue 5, can attenuate growth of pancreatic cancer cell,” Cancer Research, vol. 65, no. 1, pp. 105–112, 2005. View at Scopus
  42. T. Hibi, T. Mori, M. Fukuma et al., “Synuclein-γ is closely involved in perineural invasion and distant metastasis in mouse models and is a novel prognostic factor in pancreatic cancer,” Clinical Cancer Research, vol. 15, no. 8, pp. 2864–2871, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. J. M. Löhr, R. Faissner, P. Findeisen, et al., “Proteome analysis-basis for individualized pancreatic carcinoma therapy?” Internist, vol. 47, supplement 1, pp. S40–S48, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. D. J. Shields, S. Niessen, E. A. Murphy et al., “RBBP9: a tumor-associated serine hydrolase activity required for pancreatic neoplasia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 5, pp. 2189–2194, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. L. C. Fry, K. Mönkemüller, and P. Malfertheiner, “Molecular markers of pancreatic cancer: development and clinical relevance,” Langenbeck's Archives of Surgery, vol. 393, no. 6, pp. 883–890, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus